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FAMILIAL amyloidotic polyneuropathy (FAP) ATTRMet 30 is the result of an inherited disorder of
transthyretin metabolism. Both amyloid transthyretin and
normal transthyretin are produced in the liver and the
transplantation is a successful therapy for this disease and is
performed in spite of the completely normal liver function
of these patients.1 A high incidence of hyperfibrinolysis was
reported during liver transplantation but these studies were
performed in patients with previous liver insufficiency and
the relative role of preoperative factors (liver disease,
coagulation disorders, increased fibrinolytic activity) and
intraoperative factors (surgical trauma, hypotension, and
graft reperfusion) is not clearly established.2,3 As far as we
know, the incidence and the severity of hyperfibrinolysis
during liver transplantation in patients without preopera-
tive liver insufficiency has not yet been studied. The aim of
this study was to evaluate the incidence of hyperfibrinolysis
during liver transplantation in FAP and to correlate these
findings with several perioperative factors.
PATIENTS
Group I included 75 FAP ATTR Met 30 recipients of first liver
transplants during a 6-year period, 41 male and 34 female, with age
of 35.1 6 7.2 years, body mass index (BMI) of 20.7 6 4.1 kg/m2,
disease duration (since the first symptom) of 4.4 6 2.4 years and
neurologic score of 32.7 6 11.3 in the scale of Macedo et al.4 Every
patient in this group received prophylactic antifibrinolytic therapy.
For a control, 102 patients with liver diseases transplanted during
the same period were used as follows: 21 patients that did not
receive prophylactic antifibrinolytic therapy were considered as
group IIA; 81 patients that received high-dose aprotinin during all
the surgical procedure were considered as group IIB. Not different
concerning sex, both group IIA (43.2 6 13.8 years, P , .01) and
group IIB (43.2 6 12.5 years, P , .001) were older than group I.
Group I patients had normal liver tests: AST, 26.0 6 12.2 U/L;
ALT, 25.3 6 15.7 U/L; total bilirubin 0.8 6 0.4 mg/dL; direct
bilirubin 0.1 6 0.1 mg/dL. The same was not observed in the other
groups: AST was 124 6 228 U/L in group IIA (P 5 ns) and 191 6
467 U/L in group IIB (P , .01); ALT, 100 6 156 U/L in group IIA
(P 5 ns) and 169 6 419 U/L in group IIB (P , .01); total bilirubin
5.3 6 9.9 mg/dL in group IIA (P 5 ns) and 10.1 6 12.5 mg/dL in
group IIB (P , .001); direct bilirubin 3.0 6 6.5 mg/dL in group IIA
(P 5 ns) and 5.1 6 7.7 mg/dL in group IIB (P , .001). The values
of P account comparisons with group I.
METHOD
Anesthesia, monitoring, circulatory, and coagulation goals
and treatments were the same in the three groups. Throm-
belastograms (TEG) were retrospectively evaluated in a
blind fashion by two independent observers. As standard-
ized, one intraoperative value of a60/ma (whole blood clot
lysis index) less than 0.8 was considered a signal of hyper-
fibrinolysis. Before the evaluation of any TEG of this study,
we decided to consider one intraoperative value of F (whole
blood clot lysis time) less than 60 minutes as evidence of
severe hyperfibrinolysis. The three groups were compared
by one-way ANOVA followed by Tukey’s test. Within
group I, patients with hyperfibrinolysis were compared with
patients without hyperfibrinolysis by Mann-Whitney U test
or chi-square test, followed if necessary by Fisher exact test.
Data are presented as mean 6 standard deviation.
RESULTS
Values of a60/ma less than 0.8 were observed in at least one
TEG of 64 patients (85.5%) of group I, 13 (61.9%) of group
IIA, and 35 (43.2%) of group IIB meaning that group I
incidence was significantly different from group IIA (P ,
.05) and group IIB (P , .001). Values of F less than 60
minutes were observed in 26 patients (34.7%) of group I,
none of group IIA, and 1 (1.2%) of group IIB. Group I was
also significantly different from group IIA (P , .01) and
group IIB (P , .001). The duration of anesthesia was not
different in the three groups. Group I patients consumed
5.3 6 10.2 units of red blood cells (RBC), 13.0 6 17.6 units
of fresh frozen plasma (FFP), and 3.8 6 9.6 units of
platelets. A nonsignificant tendency toward higher values
was observed in group IIA: 9.6 6 8.3 units of RBC (P 5 ns),
19.5 6 16.0 units of FFP (P 5 ns) and 5.8 6 7.8 units of
platelets (P 6 ns). Significantly higher values were observed
in group IIB: 14.5 6 14.2 units of RBC (P , .001), 29.2 6
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22.7 units of FFP (P , .001), and 9.8 6 8.8 units of platelets
(P , .001). One-year actuarial survival in group I (88.8%)
was higher than in group IIB (63.8%, P , .001) but not
significantly higher than in group IA (81.0%, P 5 ns).
Within group I, when we compared patients with F less than
60 minutes with the remaining patients of the same group,
we observed a higher consumption of RBC (10.5 6 15.9 vs
2.5 6 2.2, P , .001), FFP (20.4 6 9.1 vs 9.1 6 6.8, P , .001)
and platelets (8.8 6 14.7 vs 1.1 6 2.8, P , .001), a longer
duration of anesthesia (10:33 hours 6 3:06 vs 8:52 6 2:24,
P , .001) and a longer duration of postoperative ventilation
(57.3 6 133.8 hours vs 8.5 6 7.8 hours, P , .001), but not
a different perioperative mortality (0% vs 2.0% P 5 ns) or
a different 1-year survival (89.3% vs 87.7%, P 5 ns). When
we compared patients with am/a60 less than 0.8 with the
other patients of group I, we did not observe any kind of
difference.
DISCUSSION
Our data show that hyperfibrinolysis is a frequent event
during liver transplantation for FAP and severe cases have
been clearly associated with increase of blood losses, dura-
tion of surgery and postoperative ventilation but not with
increased mortality. The higher incidence of hyperfibrinoly-
sis in FAP when compared with group IIB is not unexpected
as the latter group received prophylactic aprotinin, which is
effective in preventing the development of hyperfibrinoly-
sis.5 Nevertheless, the significant differences observed be-
tween groups I and IIA are rather unexpected. Surgical
procedures in group I tend to be less hemorrhagic and, as
far as we know, nothing has ever been reported suggesting
any relation between FAP and coagulation disorders. Un-
der these circumstances it was expected that FAP patients
presented less and not more hyperfibrinolysis when com-
pared with patients with liver diseases. We can hypothesize
that our findings could be related with the high incidence of
hypotension reported as a frequent complication during
liver transplants for FAP.6,7
Within group I, concerning the relations between TEG
signals of severe hyperfibrinolysis and increased consump-
tion of blood products and longer anesthesia duration, it is
important to stress that the design of our study did not allow
to determine what is cause and what is consequence.
Prophylactic antifibrinolytic regimen significantly reduce
fibrinolysis during liver transplant,5,8 but it was never
proved that they decrease blood loss. Nevertheless a signif-
icant number of liver centers believe that they do and use
them during all liver transplants. The significant incidence
of severe hyperfibrinolysis that we found in FAP patients
and the dramatic relation observed in these patients be-
tween severe hyperfibrinolysis and increased blood loss
suggest that the prophylactic use of antifibrinolytic drugs
should be evaluated in the future in FAP.
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